Last reviewed · How we verify

Huntington's chorea — Treatment Landscape & Competitive Intelligence

Huntington's chorea (disease) competitive landscape: 2 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

2 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Huntington's chorea, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Austedo DEUTETRABENAZINE Teva Synaptic vesicular amine transporter 2017-01-01
Xenazine TETRABENAZINE Bausch Health Vesicular Monoamine Transporter 2 Inhibitor [EPC] Synaptic vesicular amine transporter 2008-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Bausch Health · 1 drug in Huntington's chorea
  2. Teva · 1 drug in Huntington's chorea

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Huntington's chorea:

Cite this brief

Drug Landscape (2026). Huntington's chorea — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/huntington-s-chorea. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing